Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Tsubota Laboratory's Debt-to-EBITDA or its related term are showing as below:
TSE:4890'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.2 Med: 0.76 Max: 7.93
Current: -0.1
During the past 7 years, the highest Debt-to-EBITDA Ratio of Tsubota Laboratory was 7.93. The lowest was -0.20. And the median was 0.76.
TSE:4890's Debt-to-EBITDA is ranked worse than 100% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs TSE:4890: -0.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Tsubota Laboratory Debt-to-EBITDA Related Terms
Tsubota Laboratory Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Tsubota Laboratory's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4890 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Tsubota Laboratory's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tsubota Laboratory Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tsubota Laboratory's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tsubota Laboratory's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Tsubota Laboratory (TSE:4890) has a Debt-to-EBITDA of -0.08 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tsubota Laboratory. According to the industry distribution chart, Tsubota Laboratory ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Tsubota Laboratory's Debt-to-EBITDA too high?
Tsubota Laboratory's current Debt-to-EBITDA is -0.08. Based on the distribution chart, Tsubota Laboratory ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tsubota Laboratory has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tsubota Laboratory's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Tsubota Laboratory ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Tsubota Laboratory in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tsubota Laboratory. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsubota Laboratory's current Debt-to-EBITDA is -0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsubota Laboratory stock overvalued right now?
Based on GuruFocus' analysis, Tsubota Laboratory (TSE:4890) is currently considered Significantly Overvalued. The stock's GF Value™ is 円96.07, compared to a current price of 円277.00 — trading 188.3% above its estimated fair value. The current Debt-to-EBITDA is -0.08. Tsubota Laboratory's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Tsubota Laboratory (TSE:4890), the current Debt-to-EBITDA is -0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsubota Laboratory (TSE:4890) Overvalued in 2026?
Based on GuruFocus' analysis, Tsubota Laboratory stock appears to be overvalued.
The current stock price of 円277.00 is trading 188.3% above its estimated GF Value™ of 円96.07.
GuruFocus considers Tsubota Laboratory to be Significantly Overvalued.
Key valuation signals for TSE:4890:
Debt-to-EBITDA: -0.08
GF Value™: 円96.07 vs. price of 円277.00 (188.3% above fair value)
No single metric tells the full story. See the TSE:4890 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
61GF Score
Get the complete analysis for TSE:4890
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4890 has been successfully added to your 
